ArticleClinicoEconomics and outcomes research : CEOR2025
Evaluating the Economic Impact of Diabetes Mellitus: A Hospital-Centric Cost Analysis in Hail, Saudi Arabia.
Article in ClinicoEconomics and outcomes research : CEOR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Methylglyoxal-derived glycated albumin enhances the stemness potential of invasive ductal carcinoma-derived breast cancer stem-like cell line KAIMRC1.Oncology letters · 2026Article
- Risk assessment for type 2 diabetes mellitus and its association with knowledge and health beliefs among university students in three Arab countries.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetes mellitus (DM) is a chronic non-communicable disease (NCD) that imposes a significant economic burden on healthcare systems and households. This study aimed to estimate the direct medical costs associated with diabetes care from a hospital perspective in Hail, Saudi Arabia. Methods: A retrospective, hospital-based study was conducted using data from hospital records of diabetic patients treated at King Khalid Hospital (KKH) and King Salman Specialized Hospital (KSSH) in Hail. The study employed a top-down approach to estimate direct medical costs, including consultation, lab tests, medications, admissions, and annual check-ups. Costs were adjusted to US dollars (1 USD = 3.75 SAR). Ethical approval was obtained from the Hail Health Cluster (IRB Log Number: 2023-44). Results: A total of 377 diabetic patients were included in the study. The mean age was 58.02 years (SD = 18.80), with 53.3% male and 46.7% female patients. The average total annual cost per patient was US$6689.1 (±3450.1), with admission costs being the highest contributor (US$2686.0 ± 3373.0). The total estimated cost for all patients combined was approximately US$2.52 million. Older age, female gender, DM complications, and treatment at KSSH were significantly associated with higher direct costs. Conclusion: The economic burden of diabetes is substantial and continues to rise annually. Policymakers should prioritize cost-effective interventions and improve data collection across hospitals to better understand and mitigate the financial impact of diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.